Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TS03 Inc Trust Units TSTIF



GREY:TSTIF - Post by User

Comment by dant2on Sep 20, 2017 5:35pm
135 Views
Post# 26722486

RE:RE:RE:RE:RE:RE:RE:RE:RE:No real news yet??

RE:RE:RE:RE:RE:RE:RE:RE:RE:No real news yet??I reallize this and I am not assuming general compatibility. It is a work in progress and I trust TOS management is working expeditiously to resolve these issues on many product lines as we speak, and yes resolution in some cases may depend on the OEM's willingness to make mofifications.
I'm just making the point that even with OEM endorsements end users still face many disclaimers alluding to increased product maintenance and the potential for reduced lifecycle. And at the same time there is great pressure is on HC organizations to insure that patients are safe.
I believe that HC institutions will evolve to the safer solution even if it costs more to maintain their inventory of scopes simply because its easier to predict and budget vs the costs of litigation and lost reputation related to an outbreak - something I deem to be inevidable. 
Your point on wait times for the short scopes is well taken. My opinion is that it will be the end users and not the OEM's who drive operational standards. We've heard the claims of reduced costs related to the VP4 and certainly the simple operation and large mixed loads seems to support that. If the recent cohort of VP4 users are experiencing higher efficacy at lower costs these users will push the OEM's and we can expect a more rapid adoption. TOS management has stated that their list of reference customers continues to grow and that users are experiencing improved throughput and costs savings. I happen to believe management on this point and thus far I have seen no adverse reports on MAUDE related to the VP4.
<< Previous
Bullboard Posts
Next >>